NGS-based RNA-sequencing Market by Product & Services (Sample Preparation, Platforms & Consumables, Services, Data Analysis), Technology (SBS, SMRT, Nanopore), Application (De Novo, Epigenetics, small RNA), End-User, Region - Global Forecast to 2027
The global NGS-based RNA-sequencing market is projected to reach USD 5.5 billion by 2027 from USD 2.5 billion in 2022, at a CAGR of 17.2% during the forecast period. Growth in the NGS-based RNA-sequencing market is mainly driven by the advantages of RNA sequencing over conventional technologies, the decreasing cost of genome sequencing, increasing government funding to support genomics projects, growing research involving RNA sequencing, growing cancer cases, the increasing application of NGS in cancer research, and rapid growth in personalized medicine. On the other hand, a lack of qualified specialists, end-user budget constraints in developing countries, and standardization concerns in diagnostic testing are expected to limit the market growth.
“Nanopore sequencing segment is anticipated to grow at substantial CAGR during the forecast period.”
Based on technology, the NGS-based RNA-sequencing market has been segmented into sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, and nanopore sequencing. The nanopore sequencing segment is projected to register the highest CAGR from 2022 to 2027. Nanopore sequencing is the only sequencing technology with direct RNA-sequencing capabilities. The adoption of nanopore sequencing is increasing among end users due to its benefits as compared to other next-generation sequencing technologies, such as single-molecule sequencing of native DNA and RNA capable of detecting modifications in individual nucleotides allowing primers to cover the whole length of the 16S gene or even whole ribosomal operons, real-time targeted sequencing, large read lengths and full-length cDNA read, and reliable detection of structural variants.
“Expression profiling analysis applications segment dominated the market in 2021.”
On the basis of application, the NGS-based RNA-sequencing market is segmented into expression profiling analysis, small RNA sequencing, de novo transcriptome assembly, and variant calling & transcriptome epigenetics. In 2021, the expression profiling analysis segment accounted for the largest share of the NGS-based RNA-sequencing market. The increasing prevalence of metabolic disorders, multiple sclerosis, and other diseases are expected to propel the demand for expression profiling analysis.
“North America held the dominant share of the market in 2021.”
Geographically, the NGS-based RNA-sequencing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the major share of the NGS-based RNA-sequencing market. North America held the dominant share owing to the availability of government support, advancements in RNA sequencing products, the growing prevalence of target diseases, growing research on cancer and inherited rare diseases, and the strong presence of key players in the region. However, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period, owing to a significant focus on R&D, the decreasing costs of NGS products and services, and the increasing focus of major market players on strengthening their presence in the Asia Pacific.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the global NGS-based RNA-sequencing market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, technology, application, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total NGS-based RNA-sequencing market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
“Nanopore sequencing segment is anticipated to grow at substantial CAGR during the forecast period.”
Based on technology, the NGS-based RNA-sequencing market has been segmented into sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, and nanopore sequencing. The nanopore sequencing segment is projected to register the highest CAGR from 2022 to 2027. Nanopore sequencing is the only sequencing technology with direct RNA-sequencing capabilities. The adoption of nanopore sequencing is increasing among end users due to its benefits as compared to other next-generation sequencing technologies, such as single-molecule sequencing of native DNA and RNA capable of detecting modifications in individual nucleotides allowing primers to cover the whole length of the 16S gene or even whole ribosomal operons, real-time targeted sequencing, large read lengths and full-length cDNA read, and reliable detection of structural variants.
“Expression profiling analysis applications segment dominated the market in 2021.”
On the basis of application, the NGS-based RNA-sequencing market is segmented into expression profiling analysis, small RNA sequencing, de novo transcriptome assembly, and variant calling & transcriptome epigenetics. In 2021, the expression profiling analysis segment accounted for the largest share of the NGS-based RNA-sequencing market. The increasing prevalence of metabolic disorders, multiple sclerosis, and other diseases are expected to propel the demand for expression profiling analysis.
“North America held the dominant share of the market in 2021.”
Geographically, the NGS-based RNA-sequencing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the major share of the NGS-based RNA-sequencing market. North America held the dominant share owing to the availability of government support, advancements in RNA sequencing products, the growing prevalence of target diseases, growing research on cancer and inherited rare diseases, and the strong presence of key players in the region. However, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period, owing to a significant focus on R&D, the decreasing costs of NGS products and services, and the increasing focus of major market players on strengthening their presence in the Asia Pacific.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type – Tier 1: 45%, Tier 2: 34%, Tier 3: 21%
- By Designation – C-level: 47.0%, D-level: 33.0%, and Others: 20.0%
- By Region - North America: 35%, Europe: 32%, Asia Pacific: 25%, Latin America: 6%, and the Middle East & Africa: 2%
- Illumina, Inc. (US)
- Thermo Fisher Scientific, Inc. (US)
- PerkinElmer, Inc. (US)
- QIAGEN N.V. (Netherlands)
- Eurofins Scientific (UK)
- Oxford Nanopore Technologies (UK)
- Agilent Technologies, Inc. (US)
- BGI Group (China)
- GENEWIZ (US)
- Hamilton Company (US)
- NuGEN Technologies (US)
- Psomagen, Inc. (South Korea)
- F. Hoffmann-La Roche AG (Switzerland)
- Takara Bio, Inc. (Japan)
- Pacific Biosciences (US)
- Zymo Research Corporation (US)
- Lucigen Corporation (US)
- Genotypic Technology (India)
- Oxford Gene Technology (UK)
- Becton, Dickinson and Company (US)
This report provides a detailed picture of the global NGS-based RNA-sequencing market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, technology, application, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total NGS-based RNA-sequencing market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on NGS-based RNA-sequencing offered by the top 20 players in the NGS-based RNA-sequencing market. The report analyses the NGS-based RNA-sequencing market by product & service, technology, application, end user, and region.
- Market Development: Comprehensive information about beneficial emerging markets. The report analyzes the markets for various NGS-based RNA-sequencing products and services across key geographic regions.
- Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the NGS-based RNA-sequencing market.
- Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the NGS-based RNA-sequencing market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONAL SCOPE
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY RESEARCH
2.1.2.1 Key data from primary sources
FIGURE 2 BREAKDOWN OF PRIMARIES
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 PRODUCT-BASED MARKET ESTIMATION
FIGURE 4 PRODUCT-BASED MARKET ESTIMATION
2.2.2 APPLICATION-BASED MARKET ESTIMATION
FIGURE 5 APPLICATION-BASED MARKET ESTIMATION
2.3 PRIMARY RESEARCH VALIDATION
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
FIGURE 7 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY
FIGURE 8 NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 9 NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 10 NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 11 NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 12 REGIONAL SNAPSHOT OF NGS-BASED RNA-SEQUENCING MARKET
4 PREMIUM INSIGHTS
4.1 NGS-BASED RNA-SEQUENCING MARKET OVERVIEW
FIGURE 13 GROWING RESEARCH ACTIVITIES INVOLVING RNA-SEQUENCING TO DRIVE MARKET
4.2 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY END USER AND COUNTRY (2021)
FIGURE 14 CHINA TO DOMINATE ASIA PACIFIC MARKET IN 2021
4.3 GEOGRAPHICAL SNAPSHOT OF NGS-BASED RNA-SEQUENCING MARKET
FIGURE 15 CHINA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD
4.4 NGS-BASED RNA-SEQUENCING MARKET, BY REGION
FIGURE 16 NORTH AMERICA TO DOMINATE NGS-BASED RNA-SEQUENCING MARKET IN 2027
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 17 NGS-BASED RNA-SEQUENCING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Decreasing costs of genome sequencing
FIGURE 18 COST OF HUMAN WHOLE-GENOME SEQUENCING, 2001–2021
5.2.1.2 Advantages of RNA-sequencing over conventional technologies
5.2.1.3 Increasing government funding to support genomics projects
5.2.1.4 Growing research involving RNA-sequencing
5.2.1.5 Rising cancer cases and increasing applications of NGS in cancer research
TABLE 1 CANCER INCIDENCE, 2020 VS. 2040
5.2.1.6 Rapid growth in personalized medicine adoption
5.2.2 RESTRAINTS
5.2.2.1 Lack of qualified specialists
5.2.2.2 End-user budget constraints in developing countries
5.2.2.3 Standardization concerns of RNA-sequencing in diagnostic testing
5.2.3 OPPORTUNITIES
5.2.3.1 Adoption of blockchain technology and cloud computing
5.2.4 CHALLENGES
5.2.4.1 Storage and interpretation of sequencing data
5.2.4.2 Analysis of RNA-sequencing data to detect novel transcripts
5.2.4.3 Ethical issues and challenges in testing procedure
6 NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
TABLE 2 NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
6.2 RNA-SEQUENCING PLATFORMS & CONSUMABLES
6.2.1 INCREASING AVAILABILITY OF PLATFORMS AND GROWING CONSUMABLE USAGE TO ENSURE GROWTH
TABLE 3 RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 4 NORTH AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 5 EUROPE: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 6 ASIA PACIFIC: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 7 LATIN AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3 SAMPLE PREPARATION PRODUCTS
6.3.1 SAMPLE PREPARATION TO BE FIRST STEP OF NGS WORKFLOW
TABLE 8 SAMPLE PREPARATION PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 9 NORTH AMERICA: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 10 EUROPE: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 11 ASIA PACIFIC: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 12 LATIN AMERICA: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.2 SAMPLE PREPARATION PRODUCTS, BY WORKFLOW
6.3.2.1 Library preparation & target enrichment
6.3.2.2 Quality control
6.3.3 SAMPLE PREPARATION PRODUCTS, BY METHOD
6.3.3.1 Manual sample preparation
6.3.3.2 Microfluidic sample preparation
6.3.3.3 Robotic liquid handling sample preparation
6.4 RNA-SEQUENCING SERVICES
6.4.1 INCREASING ADOPTION OF ADVANCED INFRASTRUCTURE AND EXPERTISE AMONG END USERS TO DRIVE DEMAND
TABLE 13 RNA-SEQUENCING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 14 NORTH AMERICA: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 15 EUROPE: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 16 ASIA PACIFIC: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 17 LATIN AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.5 DATA ANALYSIS, STORAGE & MANAGEMENT
6.5.1 INTEGRATION OF CLOUD COMPUTING AND BIOINFORMATICS TO PROPEL MARKET
TABLE 18 DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 19 NORTH AMERICA: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 20 EUROPE: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 21 ASIA PACIFIC: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 22 LATIN AMERICA: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7 NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 23 NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
7.2 SEQUENCING BY SYNTHESIS
7.2.1 SBS TECHNOLOGY TO ENABLE HIGHEST PRODUCTION OF BASE PAIRS WITHIN SHORTEST TIME
TABLE 24 SEQUENCING BY SYNTHESIS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 25 NORTH AMERICA: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 26 EUROPE: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 27 ASIA PACIFIC: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 28 LATIN AMERICA: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 ION SEMICONDUCTOR SEQUENCING
7.3.1 ION SEMICONDUCTOR SEQUENCING PLATFORMS TO POSSESS HIGH-THROUGHPUT CAPABILITIES
TABLE 29 ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 30 NORTH AMERICA: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 31 EUROPE: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 32 ASIA PACIFIC: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 33 LATIN AMERICA: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 SINGLE-MOLECULE REAL-TIME SEQUENCING
7.4.1 SMRT SEQUENCING TO PRODUCE RESULTS IN SHORTER TIME AND LOWER COSTS
TABLE 34 SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 35 NORTH AMERICA: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 36 EUROPE: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 37 ASIA PACIFIC: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 38 LATIN AMERICA: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.5 NANOPORE SEQUENCING
7.5.1 NANOPORE SEQUENCING TO POSSESS DIRECT RNA-SEQUENCING CAPABILITIES
TABLE 39 NANOPORE SEQUENCING MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 40 NORTH AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 41 EUROPE: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 42 ASIA PACIFIC: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 43 LATIN AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8 NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 44 NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.2 EXPRESSION PROFILING ANALYSIS
8.2.1 INCREASING NEED FOR IMPROVED PROGNOSIS OF PATIENTS TO PROPEL MARKET
TABLE 45 EXPRESSION PROFILING ANALYSIS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 46 NORTH AMERICA: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 47 EUROPE: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 48 ASIA PACIFIC: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 49 LATIN AMERICA: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 SMALL RNA-SEQUENCING
8.3.1 RISING NEED FOR ACCURATE DIAGNOSTIC ANALYSIS TO SUPPORT MARKET
TABLE 50 SMALL RNA-SEQUENCING MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 51 NORTH AMERICA: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 52 EUROPE: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 53 ASIA PACIFIC: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 54 LATIN AMERICA: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 DE NOVO TRANSCRIPTOME ASSEMBLY
8.4.1 INCREASING CANCER CASES TO DRIVE SEGMENT
TABLE 55 DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 56 NORTH AMERICA: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 57 EUROPE: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 58 ASIA PACIFIC: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 59 LATIN AMERICA: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.5 VARIANT CALLING & TRANSCRIPTOME EPIGENETICS
8.5.1 COMPLICATED RNA SEQUENCE DATA ANALYSIS TO RESTRAIN SEGMENT
TABLE 60 VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 61 NORTH AMERICA: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 62 EUROPE: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 63 ASIA PACIFIC: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 64 LATIN AMERICA: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
9 NGS-BASED RNA-SEQUENCING MARKET, BY END USER
9.1 INTRODUCTION
TABLE 65 NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2 RESEARCH & ACADEMIA
9.2.1 INCREASING COLLABORATIONS WITH NGS PLAYERS AND RISING GOVERNMENT FUNDING TO PROPEL MARKET
TABLE 66 NGS-BASED RNA-SEQUENCING MARKET FOR RESEARCH & ACADEMIA, BY REGION, 2020–2027 (USD MILLION)
9.3 HOSPITALS & CLINICS
9.3.1 INCREASING ADOPTION OF NGS SYSTEMS TO DRIVE MARKET
TABLE 67 NGS-BASED RNA-SEQUENCING MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION)
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.4.1 CONSOLIDATION WITH NGS PLAYERS FOR TARGET THERAPIES TO PROPEL MARKET
TABLE 68 NGS-BASED RNA-SEQUENCING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
9.5 OTHER END USERS
TABLE 69 NGS-BASED RNA-SEQUENCING MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
10 NGS-BASED RNA-SEQUENCING MARKET, BY REGION
10.1 INTRODUCTION
TABLE 70 NGS-BASED RNA-SEQUENCING MARKET, BY REGION, 2020–2027(USD MILLION)
10.2 NORTH AMERICA
FIGURE 19 NORTH AMERICA: MARKET SNAPSHOT
TABLE 71 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027(USD MILLION)
TABLE 72 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 73 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 74 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
TABLE 75 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020–2027(USD MILLION)
10.2.1 US
10.2.1.1 Favorable funding scenario and growing R&D activity to drive market
TABLE 76 US: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 77 US: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 78 US: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.2.2 CANADA
10.2.2.1 Government initiatives for genome research to boost market
TABLE 79 CANADA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 80 CANADA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 81 CANADA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.3 EUROPE
TABLE 82 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027(USD MILLION)
TABLE 83 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 84 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 85 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
TABLE 86 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020–2027(USD MILLION)
10.3.1 GERMANY
10.3.1.1 Germany to dominate European market during forecast period
TABLE 87 GERMANY: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 88 GERMANY: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 89 GERMANY: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.3.2 UK
10.3.2.1 Strong presence of NGS organizations and their initiatives to stimulate market
TABLE 90 UK: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 91 UK: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 92 UK: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.3.3 FRANCE
10.3.3.1 Growing awareness of high-throughput sequencing in genetic characterization to accelerate growth
TABLE 93 FRANCE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 94 FRANCE: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 95 FRANCE: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.3.4 REST OF EUROPE
TABLE 96 REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 97 REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 98 REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.4 ASIA PACIFIC
FIGURE 20 ASIA PACIFIC: MARKET SNAPSHOT
TABLE 99 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027(USD MILLION)
TABLE 100 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 101 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 102 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
TABLE 103 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020–2027(USD MILLION)
10.4.1 CHINA
10.4.1.1 Established players and favorable government initiatives to drive market
TABLE 104 CHINA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 105 CHINA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 106 CHINA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.4.2 JAPAN
10.4.2.1 Growing awareness and rising incidence of genetic disorders to propel market
TABLE 107 JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 108 JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 109 JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.4.3 INDIA
10.4.3.1 Rising interest of companies for collaborations to drive market
TABLE 110 INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 111 INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 112 INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 113 REST OF ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 114 REST OF ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 115 REST OF ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.5 LATIN AMERICA
TABLE 116 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027(USD MILLION)
TABLE 117 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 118 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 119 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
TABLE 120 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020–2027(USD MILLION)
10.5.1 BRAZIL
10.5.1.1 High HIV prevalence to drive demand for NGS in research
TABLE 121 BRAZIL: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 122 BRAZIL: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 123 BRAZIL: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.5.2 MEXICO
10.5.2.1 Economic growth and support for infrastructural development to propel market
TABLE 124 MEXICO: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 125 MEXICO: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 126 MEXICO: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.5.3 REST OF LATIN AMERICA
TABLE 127 REST OF LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 128 REST OF LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 129 REST OF LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 LACK OF INFRASTRUCTURE TO RESTRAIN MARKET
TABLE 130 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 131 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 132 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
TABLE 133 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020–2027(USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
FIGURE 21 KEY DEVELOPMENTS IN NGS-BASED RNA-SEQUENCING MARKET, 2019–2022
11.3 MARKET SHARE ANALYSIS
FIGURE 22 NGS-BASED RNA-SEQUENCING MARKET SHARE, BY KEY PLAYER, 2021
TABLE 134 NGS-BASED RNA-SEQUENCING MARKET: DEGREE OF COMPETITION
11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
11.5 COMPETITIVE LEADERSHIP MAPPING
11.5.1 TERMINOLOGY/NOMENCLATURE
11.5.1.1 Visionary leaders
11.5.1.2 Innovators
11.5.1.3 Dynamic differentiators
11.5.1.4 Emerging companies
FIGURE 24 NGS-BASED RNA-SEQUENCING MARKET, COMPETITIVE LEADERSHIP MAPPING, 2021 (OVERALL MARKET)
FIGURE 25 NGS-BASED RNA-SEQUENCING MARKET, COMPETITIVE LEADERSHIP MAPPING, 2021 (SMES/START-UPS)
11.6 COMPETITIVE SCENARIO
TABLE 135 NGS-BASED RNA-SEQUENCING MARKET: PRODUCT/SERVICE LAUNCHES
TABLE 136 NGS-BASED RNA-SEQUENCING MARKET: DEALS
TABLE 137 NGS-BASED RNA-SEQUENCING MARKET: OTHER DEVELOPMENTS
12 COMPANY PROFILES
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
12.1 KEY PLAYERS
12.1.1 ILLUMINA, INC.
TABLE 138 ILLUMINA, INC.: COMPANY OVERVIEW
FIGURE 26 ILLUMINA, INC.: COMPANY SNAPSHOT, 2021
TABLE 139 ILLUMINA, INC.: PRODUCT LAUNCHES
TABLE 140 ILLUMINA, INC.: DEALS
TABLE 141 ILLUMINA, INC.: OTHER DEVELOPMENTS
12.1.2 QIAGEN N.V.
TABLE 142 QIAGEN N.V.: COMPANY OVERVIEW
FIGURE 27 QIAGEN N.V.: COMPANY SNAPSHOT, 2021
TABLE 143 QIAGEN N.V.: PRODUCT LAUNCHES & ENHANCEMENTS
TABLE 144 QIAGEN N.V.: DEALS
12.1.3 PERKINELMER, INC.
TABLE 145 PERKINELMER, INC.: COMPANY OVERVIEW
FIGURE 28 PERKINELMER, INC.: COMPANY SNAPSHOT, 2021
TABLE 146 PERKINELMER, INC.: PRODUCT LAUNCHES
12.1.4 EUROFINS SCIENTIFIC
TABLE 147 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
FIGURE 29 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT, 2021
TABLE 148 EUROFINS SCIENTIFIC: DEALS
12.1.5 OXFORD NANOPORE TECHNOLOGIES
TABLE 149 OXFORD NANOPORE TECHNOLOGIES: COMPANY OVERVIEW
TABLE 150 OXFORD NANOPORE TECHNOLOGIES: PRODUCT LAUNCHES
TABLE 151 OXFORD NANOPORE TECHNOLOGIES: DEALS
TABLE 152 OXFORD NANOPORE TECHNOLOGIES: OTHER DEVELOPMENTS
12.1.6 AGILENT TECHNOLOGIES, INC.
TABLE 153 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
FIGURE 30 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT, 2021
12.1.7 BGI GROUP
TABLE 154 BGI GROUP: COMPANY OVERVIEW
TABLE 155 BGI GROUP: DEALS
12.1.8 GENEWIZ (PART OF BROOKS AUTOMATION)
TABLE 156 GENEWIZ: COMPANY OVERVIEW
TABLE 157 GENEWIZ: SERVICES LAUNCHED
12.1.9 HAMILTON COMPANY
TABLE 158 HAMILTON COMPANY: COMPANY OVERVIEW
12.1.10 NUGEN TECHNOLOGIES (PART OF TECAN TRADING AG)
TABLE 159 NUGEN TECHNOLOGIES: COMPANY OVERVIEW
12.1.11 PSOMAGEN (FORMERLY KNOWN AS MACROGEN)
TABLE 160 PSOMAGEN: COMPANY OVERVIEW
12.1.12 F. HOFFMANN-LA ROCHE AG
TABLE 161 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW
FIGURE 31 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT, 2021
TABLE 162 F. HOFFMANN-LA ROCHE AG: DEALS
12.1.13 THERMO FISHER SCIENTIFIC, INC.
TABLE 163 THERMO FISHER SCIENTIFIC, INC.: COMPANY OVERVIEW
FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT, 2021
TABLE 164 THERMO FISHER SCIENTIFIC, INC.: DEALS
12.1.14 TAKARA BIO, INC.
TABLE 165 TAKARA BIO, INC.: COMPANY OVERVIEW
FIGURE 33 TAKARA BIO, INC.: COMPANY SNAPSHOT, 2021
12.1.15 PACIFIC BIOSCIENCES
TABLE 166 PACIFIC BIOSCIENCES: COMPANY OVERVIEW
FIGURE 34 PACIFIC BIOSCIENCES: COMPANY SNAPSHOT, 2021
12.2 OTHER PLAYERS
12.2.1 ZYMO RESEARCH
12.2.2 LUCIGEN CORPORATION
12.2.3 GENOTYPIC TECHNOLOGY
12.2.4 OXFORD GENE TECHNOLOGY (PART OF SYSMEX)
12.2.5 BECTON, DICKINSON AND COMPANY
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONAL SCOPE
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY RESEARCH
2.1.2.1 Key data from primary sources
FIGURE 2 BREAKDOWN OF PRIMARIES
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 PRODUCT-BASED MARKET ESTIMATION
FIGURE 4 PRODUCT-BASED MARKET ESTIMATION
2.2.2 APPLICATION-BASED MARKET ESTIMATION
FIGURE 5 APPLICATION-BASED MARKET ESTIMATION
2.3 PRIMARY RESEARCH VALIDATION
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
FIGURE 7 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY
FIGURE 8 NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 9 NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 10 NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 11 NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 12 REGIONAL SNAPSHOT OF NGS-BASED RNA-SEQUENCING MARKET
4 PREMIUM INSIGHTS
4.1 NGS-BASED RNA-SEQUENCING MARKET OVERVIEW
FIGURE 13 GROWING RESEARCH ACTIVITIES INVOLVING RNA-SEQUENCING TO DRIVE MARKET
4.2 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY END USER AND COUNTRY (2021)
FIGURE 14 CHINA TO DOMINATE ASIA PACIFIC MARKET IN 2021
4.3 GEOGRAPHICAL SNAPSHOT OF NGS-BASED RNA-SEQUENCING MARKET
FIGURE 15 CHINA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD
4.4 NGS-BASED RNA-SEQUENCING MARKET, BY REGION
FIGURE 16 NORTH AMERICA TO DOMINATE NGS-BASED RNA-SEQUENCING MARKET IN 2027
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 17 NGS-BASED RNA-SEQUENCING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Decreasing costs of genome sequencing
FIGURE 18 COST OF HUMAN WHOLE-GENOME SEQUENCING, 2001–2021
5.2.1.2 Advantages of RNA-sequencing over conventional technologies
5.2.1.3 Increasing government funding to support genomics projects
5.2.1.4 Growing research involving RNA-sequencing
5.2.1.5 Rising cancer cases and increasing applications of NGS in cancer research
TABLE 1 CANCER INCIDENCE, 2020 VS. 2040
5.2.1.6 Rapid growth in personalized medicine adoption
5.2.2 RESTRAINTS
5.2.2.1 Lack of qualified specialists
5.2.2.2 End-user budget constraints in developing countries
5.2.2.3 Standardization concerns of RNA-sequencing in diagnostic testing
5.2.3 OPPORTUNITIES
5.2.3.1 Adoption of blockchain technology and cloud computing
5.2.4 CHALLENGES
5.2.4.1 Storage and interpretation of sequencing data
5.2.4.2 Analysis of RNA-sequencing data to detect novel transcripts
5.2.4.3 Ethical issues and challenges in testing procedure
6 NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
TABLE 2 NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
6.2 RNA-SEQUENCING PLATFORMS & CONSUMABLES
6.2.1 INCREASING AVAILABILITY OF PLATFORMS AND GROWING CONSUMABLE USAGE TO ENSURE GROWTH
TABLE 3 RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 4 NORTH AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 5 EUROPE: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 6 ASIA PACIFIC: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 7 LATIN AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3 SAMPLE PREPARATION PRODUCTS
6.3.1 SAMPLE PREPARATION TO BE FIRST STEP OF NGS WORKFLOW
TABLE 8 SAMPLE PREPARATION PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 9 NORTH AMERICA: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 10 EUROPE: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 11 ASIA PACIFIC: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 12 LATIN AMERICA: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.2 SAMPLE PREPARATION PRODUCTS, BY WORKFLOW
6.3.2.1 Library preparation & target enrichment
6.3.2.2 Quality control
6.3.3 SAMPLE PREPARATION PRODUCTS, BY METHOD
6.3.3.1 Manual sample preparation
6.3.3.2 Microfluidic sample preparation
6.3.3.3 Robotic liquid handling sample preparation
6.4 RNA-SEQUENCING SERVICES
6.4.1 INCREASING ADOPTION OF ADVANCED INFRASTRUCTURE AND EXPERTISE AMONG END USERS TO DRIVE DEMAND
TABLE 13 RNA-SEQUENCING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 14 NORTH AMERICA: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 15 EUROPE: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 16 ASIA PACIFIC: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 17 LATIN AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.5 DATA ANALYSIS, STORAGE & MANAGEMENT
6.5.1 INTEGRATION OF CLOUD COMPUTING AND BIOINFORMATICS TO PROPEL MARKET
TABLE 18 DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 19 NORTH AMERICA: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 20 EUROPE: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 21 ASIA PACIFIC: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 22 LATIN AMERICA: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7 NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 23 NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
7.2 SEQUENCING BY SYNTHESIS
7.2.1 SBS TECHNOLOGY TO ENABLE HIGHEST PRODUCTION OF BASE PAIRS WITHIN SHORTEST TIME
TABLE 24 SEQUENCING BY SYNTHESIS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 25 NORTH AMERICA: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 26 EUROPE: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 27 ASIA PACIFIC: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 28 LATIN AMERICA: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 ION SEMICONDUCTOR SEQUENCING
7.3.1 ION SEMICONDUCTOR SEQUENCING PLATFORMS TO POSSESS HIGH-THROUGHPUT CAPABILITIES
TABLE 29 ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 30 NORTH AMERICA: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 31 EUROPE: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 32 ASIA PACIFIC: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 33 LATIN AMERICA: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 SINGLE-MOLECULE REAL-TIME SEQUENCING
7.4.1 SMRT SEQUENCING TO PRODUCE RESULTS IN SHORTER TIME AND LOWER COSTS
TABLE 34 SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 35 NORTH AMERICA: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 36 EUROPE: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 37 ASIA PACIFIC: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 38 LATIN AMERICA: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.5 NANOPORE SEQUENCING
7.5.1 NANOPORE SEQUENCING TO POSSESS DIRECT RNA-SEQUENCING CAPABILITIES
TABLE 39 NANOPORE SEQUENCING MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 40 NORTH AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 41 EUROPE: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 42 ASIA PACIFIC: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 43 LATIN AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8 NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 44 NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.2 EXPRESSION PROFILING ANALYSIS
8.2.1 INCREASING NEED FOR IMPROVED PROGNOSIS OF PATIENTS TO PROPEL MARKET
TABLE 45 EXPRESSION PROFILING ANALYSIS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 46 NORTH AMERICA: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 47 EUROPE: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 48 ASIA PACIFIC: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 49 LATIN AMERICA: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 SMALL RNA-SEQUENCING
8.3.1 RISING NEED FOR ACCURATE DIAGNOSTIC ANALYSIS TO SUPPORT MARKET
TABLE 50 SMALL RNA-SEQUENCING MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 51 NORTH AMERICA: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 52 EUROPE: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 53 ASIA PACIFIC: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 54 LATIN AMERICA: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 DE NOVO TRANSCRIPTOME ASSEMBLY
8.4.1 INCREASING CANCER CASES TO DRIVE SEGMENT
TABLE 55 DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 56 NORTH AMERICA: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 57 EUROPE: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 58 ASIA PACIFIC: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 59 LATIN AMERICA: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.5 VARIANT CALLING & TRANSCRIPTOME EPIGENETICS
8.5.1 COMPLICATED RNA SEQUENCE DATA ANALYSIS TO RESTRAIN SEGMENT
TABLE 60 VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 61 NORTH AMERICA: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 62 EUROPE: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 63 ASIA PACIFIC: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 64 LATIN AMERICA: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
9 NGS-BASED RNA-SEQUENCING MARKET, BY END USER
9.1 INTRODUCTION
TABLE 65 NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2 RESEARCH & ACADEMIA
9.2.1 INCREASING COLLABORATIONS WITH NGS PLAYERS AND RISING GOVERNMENT FUNDING TO PROPEL MARKET
TABLE 66 NGS-BASED RNA-SEQUENCING MARKET FOR RESEARCH & ACADEMIA, BY REGION, 2020–2027 (USD MILLION)
9.3 HOSPITALS & CLINICS
9.3.1 INCREASING ADOPTION OF NGS SYSTEMS TO DRIVE MARKET
TABLE 67 NGS-BASED RNA-SEQUENCING MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION)
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.4.1 CONSOLIDATION WITH NGS PLAYERS FOR TARGET THERAPIES TO PROPEL MARKET
TABLE 68 NGS-BASED RNA-SEQUENCING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
9.5 OTHER END USERS
TABLE 69 NGS-BASED RNA-SEQUENCING MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
10 NGS-BASED RNA-SEQUENCING MARKET, BY REGION
10.1 INTRODUCTION
TABLE 70 NGS-BASED RNA-SEQUENCING MARKET, BY REGION, 2020–2027(USD MILLION)
10.2 NORTH AMERICA
FIGURE 19 NORTH AMERICA: MARKET SNAPSHOT
TABLE 71 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027(USD MILLION)
TABLE 72 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 73 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 74 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
TABLE 75 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020–2027(USD MILLION)
10.2.1 US
10.2.1.1 Favorable funding scenario and growing R&D activity to drive market
TABLE 76 US: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 77 US: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 78 US: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.2.2 CANADA
10.2.2.1 Government initiatives for genome research to boost market
TABLE 79 CANADA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 80 CANADA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 81 CANADA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.3 EUROPE
TABLE 82 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027(USD MILLION)
TABLE 83 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 84 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 85 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
TABLE 86 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020–2027(USD MILLION)
10.3.1 GERMANY
10.3.1.1 Germany to dominate European market during forecast period
TABLE 87 GERMANY: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 88 GERMANY: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 89 GERMANY: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.3.2 UK
10.3.2.1 Strong presence of NGS organizations and their initiatives to stimulate market
TABLE 90 UK: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 91 UK: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 92 UK: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.3.3 FRANCE
10.3.3.1 Growing awareness of high-throughput sequencing in genetic characterization to accelerate growth
TABLE 93 FRANCE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 94 FRANCE: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 95 FRANCE: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.3.4 REST OF EUROPE
TABLE 96 REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 97 REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 98 REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.4 ASIA PACIFIC
FIGURE 20 ASIA PACIFIC: MARKET SNAPSHOT
TABLE 99 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027(USD MILLION)
TABLE 100 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 101 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 102 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
TABLE 103 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020–2027(USD MILLION)
10.4.1 CHINA
10.4.1.1 Established players and favorable government initiatives to drive market
TABLE 104 CHINA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 105 CHINA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 106 CHINA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.4.2 JAPAN
10.4.2.1 Growing awareness and rising incidence of genetic disorders to propel market
TABLE 107 JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 108 JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 109 JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.4.3 INDIA
10.4.3.1 Rising interest of companies for collaborations to drive market
TABLE 110 INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 111 INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 112 INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 113 REST OF ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 114 REST OF ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 115 REST OF ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.5 LATIN AMERICA
TABLE 116 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027(USD MILLION)
TABLE 117 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 118 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 119 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
TABLE 120 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020–2027(USD MILLION)
10.5.1 BRAZIL
10.5.1.1 High HIV prevalence to drive demand for NGS in research
TABLE 121 BRAZIL: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 122 BRAZIL: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 123 BRAZIL: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.5.2 MEXICO
10.5.2.1 Economic growth and support for infrastructural development to propel market
TABLE 124 MEXICO: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 125 MEXICO: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 126 MEXICO: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.5.3 REST OF LATIN AMERICA
TABLE 127 REST OF LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 128 REST OF LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 129 REST OF LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 LACK OF INFRASTRUCTURE TO RESTRAIN MARKET
TABLE 130 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
TABLE 131 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
TABLE 132 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION)
TABLE 133 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020–2027(USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
FIGURE 21 KEY DEVELOPMENTS IN NGS-BASED RNA-SEQUENCING MARKET, 2019–2022
11.3 MARKET SHARE ANALYSIS
FIGURE 22 NGS-BASED RNA-SEQUENCING MARKET SHARE, BY KEY PLAYER, 2021
TABLE 134 NGS-BASED RNA-SEQUENCING MARKET: DEGREE OF COMPETITION
11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
11.5 COMPETITIVE LEADERSHIP MAPPING
11.5.1 TERMINOLOGY/NOMENCLATURE
11.5.1.1 Visionary leaders
11.5.1.2 Innovators
11.5.1.3 Dynamic differentiators
11.5.1.4 Emerging companies
FIGURE 24 NGS-BASED RNA-SEQUENCING MARKET, COMPETITIVE LEADERSHIP MAPPING, 2021 (OVERALL MARKET)
FIGURE 25 NGS-BASED RNA-SEQUENCING MARKET, COMPETITIVE LEADERSHIP MAPPING, 2021 (SMES/START-UPS)
11.6 COMPETITIVE SCENARIO
TABLE 135 NGS-BASED RNA-SEQUENCING MARKET: PRODUCT/SERVICE LAUNCHES
TABLE 136 NGS-BASED RNA-SEQUENCING MARKET: DEALS
TABLE 137 NGS-BASED RNA-SEQUENCING MARKET: OTHER DEVELOPMENTS
12 COMPANY PROFILES
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
12.1 KEY PLAYERS
12.1.1 ILLUMINA, INC.
TABLE 138 ILLUMINA, INC.: COMPANY OVERVIEW
FIGURE 26 ILLUMINA, INC.: COMPANY SNAPSHOT, 2021
TABLE 139 ILLUMINA, INC.: PRODUCT LAUNCHES
TABLE 140 ILLUMINA, INC.: DEALS
TABLE 141 ILLUMINA, INC.: OTHER DEVELOPMENTS
12.1.2 QIAGEN N.V.
TABLE 142 QIAGEN N.V.: COMPANY OVERVIEW
FIGURE 27 QIAGEN N.V.: COMPANY SNAPSHOT, 2021
TABLE 143 QIAGEN N.V.: PRODUCT LAUNCHES & ENHANCEMENTS
TABLE 144 QIAGEN N.V.: DEALS
12.1.3 PERKINELMER, INC.
TABLE 145 PERKINELMER, INC.: COMPANY OVERVIEW
FIGURE 28 PERKINELMER, INC.: COMPANY SNAPSHOT, 2021
TABLE 146 PERKINELMER, INC.: PRODUCT LAUNCHES
12.1.4 EUROFINS SCIENTIFIC
TABLE 147 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
FIGURE 29 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT, 2021
TABLE 148 EUROFINS SCIENTIFIC: DEALS
12.1.5 OXFORD NANOPORE TECHNOLOGIES
TABLE 149 OXFORD NANOPORE TECHNOLOGIES: COMPANY OVERVIEW
TABLE 150 OXFORD NANOPORE TECHNOLOGIES: PRODUCT LAUNCHES
TABLE 151 OXFORD NANOPORE TECHNOLOGIES: DEALS
TABLE 152 OXFORD NANOPORE TECHNOLOGIES: OTHER DEVELOPMENTS
12.1.6 AGILENT TECHNOLOGIES, INC.
TABLE 153 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
FIGURE 30 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT, 2021
12.1.7 BGI GROUP
TABLE 154 BGI GROUP: COMPANY OVERVIEW
TABLE 155 BGI GROUP: DEALS
12.1.8 GENEWIZ (PART OF BROOKS AUTOMATION)
TABLE 156 GENEWIZ: COMPANY OVERVIEW
TABLE 157 GENEWIZ: SERVICES LAUNCHED
12.1.9 HAMILTON COMPANY
TABLE 158 HAMILTON COMPANY: COMPANY OVERVIEW
12.1.10 NUGEN TECHNOLOGIES (PART OF TECAN TRADING AG)
TABLE 159 NUGEN TECHNOLOGIES: COMPANY OVERVIEW
12.1.11 PSOMAGEN (FORMERLY KNOWN AS MACROGEN)
TABLE 160 PSOMAGEN: COMPANY OVERVIEW
12.1.12 F. HOFFMANN-LA ROCHE AG
TABLE 161 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW
FIGURE 31 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT, 2021
TABLE 162 F. HOFFMANN-LA ROCHE AG: DEALS
12.1.13 THERMO FISHER SCIENTIFIC, INC.
TABLE 163 THERMO FISHER SCIENTIFIC, INC.: COMPANY OVERVIEW
FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT, 2021
TABLE 164 THERMO FISHER SCIENTIFIC, INC.: DEALS
12.1.14 TAKARA BIO, INC.
TABLE 165 TAKARA BIO, INC.: COMPANY OVERVIEW
FIGURE 33 TAKARA BIO, INC.: COMPANY SNAPSHOT, 2021
12.1.15 PACIFIC BIOSCIENCES
TABLE 166 PACIFIC BIOSCIENCES: COMPANY OVERVIEW
FIGURE 34 PACIFIC BIOSCIENCES: COMPANY SNAPSHOT, 2021
12.2 OTHER PLAYERS
12.2.1 ZYMO RESEARCH
12.2.2 LUCIGEN CORPORATION
12.2.3 GENOTYPIC TECHNOLOGY
12.2.4 OXFORD GENE TECHNOLOGY (PART OF SYSMEX)
12.2.5 BECTON, DICKINSON AND COMPANY
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
